RedHill Biopharma Ltd (RDHL)

[H2R]

Latest Catalyst Calendar

From the Company Presentation dated April 25, 2017, p. 5:
http://files.shareholder.com/downloads/AMDA-1C0OBF/4198042611x0x932709/53E26FCE-822F-4312-8D69-59A81B4D43A9/RedHill_Biopharma_Corporate_Presentation_230417_.pdf

Q2 - 2017

RHB-104:
• Second DSMB meeting for the MAP US Phase III study for Crohn’s disease, including safety and
interim efficacy analysis, with evaluation of option of early stop for success for overwhelming
efficacy - mid-2017

RHB-105:
• Initiation of a confirmatory Phase III study with RHB-105 for treatment of H. pylori infection

BEKINDA® (RHB-102):
• Top-line Phase III results (gastroenteritis)

Donnatal®
* and EnteraGam®:
• Gradual initiation of promotion in the U.S. - mid-2017

Q3 - 2017

BEKINDA® (RHB-102):
• Top-line Phase II results (IBS-D)

YELIVA® (ABC294640):
• Initiation of Phase Ib study to evaluate YELIVA® as a radioprotectant for prevention of mucositis in
head and neck cancer patients undergoing therapeutic radiotherapy
• Initiation of Phase IIa study with YELIVA® for cholangiocarcinoma

RIZAPORT® (RHB-103):
• Re-submission of U.S. NDA